ASH 2020 | 5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the long-term follow-up results of a phase III trial (NCT01949805) and extension study of ropeginterferon alfa-2b compared to standard cytoreductive therapy in polycythemia vera (PV). Ropeginterferon alfa-2b is a novel long-acting interferon, with a pharmacokinetic profile that offers improved tolerability, which can selectively target malignant clones. A high rate of sustained molecular response was observed in the ropeg treated patients. This treatment achieves deep and durable responses, making disease progression rare with long-term treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Srdan Verstovsek, MD, PhD, has received research support for clinical studies from Incyte, Roche, NS, Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Ital Pharma, Protagonist and Kartos.
